These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20832986)

  • 1. Evaluation of central serotonin sensitivity in breast cancer survivors with cancer-related fatigue syndrome.
    Alexander S; Stone P; White S; Andrews P; Nussey S; Bano G
    J Pain Symptom Manage; 2010 Dec; 40(6):892-8. PubMed ID: 20832986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cortisol on buspirone stimulated prolactin release: a double-blind placebo-controlled study.
    Dinan TG; Scott LV; Thakore J; Naesdal J; Keeling PW
    Psychoneuroendocrinology; 2001 Oct; 26(7):751-6. PubMed ID: 11500255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diurnal cortisol rhythm and fatigue in breast cancer survivors.
    Bower JE; Ganz PA; Dickerson SS; Petersen L; Aziz N; Fahey JL
    Psychoneuroendocrinology; 2005 Jan; 30(1):92-100. PubMed ID: 15358446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia--are central serotoninergic responses enhanced?
    Dinan TG; Mahmud N; Rathore O; Thakore J; Scott LV; Carr E; Naesdal J; O'Morain CA; Keeling PW
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1613-8. PubMed ID: 11564001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids.
    Bower JE; Ganz PA; Aziz N; Olmstead R; Irwin MR; Cole SW
    Brain Behav Immun; 2007 Mar; 21(3):251-8. PubMed ID: 17008048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin response to buspirone challenge in the presence of dopaminergic blockade.
    Maskall DD; Zis AP; Lam RW; Clark CM; Kuan AJ
    Biol Psychiatry; 1995 Aug; 38(4):235-9. PubMed ID: 8547445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life.
    Kim SH; Son BH; Hwang SY; Han W; Yang JH; Lee S; Yun YH
    J Pain Symptom Manage; 2008 Jun; 35(6):644-55. PubMed ID: 18358687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased prolactin response to buspirone in chronic fatigue syndrome.
    Sharpe M; Clements A; Hawton K; Young AH; Sargent P; Cowen PJ
    J Affect Disord; 1996 Nov; 41(1):71-6. PubMed ID: 8938208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study.
    Bennett B; Goldstein D; Friedlander M; Hickie I; Lloyd A
    J Pain Symptom Manage; 2007 Aug; 34(2):126-35. PubMed ID: 17544246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary study of buspirone stimulated prolactin release in generalised social phobia: evidence for enhanced serotonergic responsivity?
    Condren RM; Dinan TG; Thakore JH
    Eur Neuropsychopharmacol; 2002 Aug; 12(4):349-54. PubMed ID: 12126875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of buspirone on perceived exertion and time to fatigue in man.
    Marvin G; Sharma A; Aston W; Field C; Kendall MJ; Jones DA
    Exp Physiol; 1997 Nov; 82(6):1057-60. PubMed ID: 9413736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer related fatigue: a focus on breast cancer and Hodgkin's disease survivors.
    Ganz PA; Bower JE
    Acta Oncol; 2007; 46(4):474-9. PubMed ID: 17497314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communication with breast cancer survivors.
    Clayton MF
    Commun Nurs Res; 2006; 39():83-91. PubMed ID: 16729519
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantifying the 5-HT1A agonist action of buspirone in man.
    Bridge MW; Marvin G; Thompson CE; Sharma A; Jones DA; Kendall MJ
    Psychopharmacology (Berl); 2001 Nov; 158(3):224-9. PubMed ID: 11713611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal response to buspirone is not impaired in major depression.
    Navinés R; Gómez-Gil E; Martín-Santos R; de Osaba MJ; Escolar G; Gastó C
    Hum Psychopharmacol; 2007 Aug; 22(6):389-95. PubMed ID: 17563921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers.
    Anderson IM; Deakin JF; Miller HE
    Psychopharmacology (Berl); 1996 Nov; 128(1):74-82. PubMed ID: 8944409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model.
    O'Mahony S; Chua AS; Quigley EM; Clarke G; Shanahan F; Keeling PW; Dinan TG
    Neurogastroenterol Motil; 2008 Jun; 20(6):680-8. PubMed ID: 18194152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue.
    Bower JE; Ganz PA; Aziz N
    Psychosom Med; 2005; 67(2):277-80. PubMed ID: 15784794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory biomarkers for persistent fatigue in breast cancer survivors.
    Collado-Hidalgo A; Bower JE; Ganz PA; Cole SW; Irwin MR
    Clin Cancer Res; 2006 May; 12(9):2759-66. PubMed ID: 16675568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.